Introduction
Adoptive cell therapy with chimeric antigen receptor (CAR)-redirected T cells showed remarkable anti-tumor efficacy in recent clinical trials. 1 Patients' T cells are ex vivo engineered with a CAR which redirects the T cell through the extracellular antibody-derived binding domain toward target cells in a major histocompatibility complex (MHC)-independent fashion.
2 CAR intracellular signaling domain, which most frequently is the CD3f endodomain derived from the T-cell receptor (TCR) complex, mediates T-cell activation upon target engagement and initiates a plethora of effector functions including the secretion of proinflammatory cytokines, cytolysis of target cells and amplification of redirected T cells. Both CD8 + and CD4 + T cells can specifically be redirected by an engineered CAR; both T-cell subsets are required for a potent and sustained anti-tumor response. 3 CAR redirected T-cell activation, however, is short-term when no appropriate costimulation simultaneously to CD3f signaling occurs and when target cells lack costimulatory ligands. A costimulatory endodomain like CD28 was therefore fused to the CD3f CAR endodomain to prolong T-cell survival and to produce efficient killing, cytokine release and T-cell proliferation. [4] [5] [6] [7] Signaling through the fused CD28 endodomain thereby strengthens the CAR redirected T-cell response through the induction of IL-2 and the increase of IFNc. 4 Upon CD28 and CD3f TCR mediated activation T cells upregulate "late" costimulatory molecules of the tumor necrosis factor receptor family including 4-1BB (CD137) and OX40 (CD134) which are involved in prolonging T-cell persistence and inducing T-cell memory. [8] [9] [10] For instance OX40 is upregulated 24 h after antigen engagement in presence of CD28 costimulation 11, 12 and further augments CD28 activated T-cell responses with respect to proliferation, cytokine responses and survival. 13, 14 Several lines of evidences imply that the success of a redirected T-cell therapy of cancer depends on the maintenance of T cell effector functions in the long-term which can be ensured by integrating the primary TCR and CD28 signal with late costimulatory signals. Consequently, Pule et al. 15 hypothesized that the combination of CD28 and OX40 endodomains in cis with CD3f in a CAR will improve redirected T-cell effector functions and enhance antitumor activity. The T-cell response is physiologically limited by various mechanisms, one of which are repressive cytokines like IL-10 which are present in high concentrations in the tumor microenvironment, are produced by both tumor and stroma cells and which impair an anti-tumor response.
16 CD28 costimulation of T cells also induces IL-10 secretion 17 which in turn compromises T-cell based immunity 18 through downregulation of MHC molecules, 19 of the CD28 ligands CD80 and CD86 and of the intercellular adhesion molecule-1 (ICAM-1) on antigen-presenting cells (APCs). 20, 21 As a consequence the antigen-driven T-cell amplification is turned off, the secretion of pro-inflammatory cytokines is repressed and anti-inflammatory cytokines are released which contribute to a further polarization of the immune response. In addition to effector T cells, CD4 + regulatory T (Treg) cells are potent IL-10 producers moreover repressing the T-cell attack. 22 Adoptive T-cell therapy of cancer aims to tip the balance by promoting T-cell activation while reducing repression, both contributing to the overall therapeutic success. We here revealed that (1) CD28-f CAR redirected T cells upregulate IL-10 secretion upon antigen engagement, (2) IL-10 is also induced when f CAR T cells are activated in presence of IL-2, and (3) that IL-10 induced by either mechanism can be abrogated by co-signaling through OX40 in both CD4 + helper and regulatory T cells. Consequently, combined signaling through a CD28-f-OX40 CAR repressed IL-10 without affecting the other T-cell effector functions like secretion of pro-inflammatory cytokines. We assume such dual costimulatory CAR of benefit in improving T-cell anti-tumor immunity in long-term.
Results
We screened the cytokine profiles of CAR redirected human CD4 + T cells upon engagement of CAR-defined antigen. While the CARs have the same extracellular binding domain for carcinoembryonic antigen (CEA), the signaling moiety is composed of the CD3f endodomain fused to the intracellular CD28 or OX40 chain, respectively, providing different costimuli (Fig. 1A) . Upon retroviral transduction, CARs were expressed on the surface of human T cells with nearly same efficiencies (Fig. 1B) . A CD3f CAR without costimulatory domain was expressed in CD4 + T cells for comparison. Engineered T cells were co-incubated with CEA + and CEA -tumor cells, respectively, to record CAR-driven T-cell activation. Engineered T cells were activated to secrete IFNc upon co-incubation with CEA + but not with CEA -tumor cells demonstrating the specificity of CAR mediated T-cell activation ( Fig. 2A) . IFNc secretion was substantially enhanced by CD28 and OX40 costimulation, respectively. IL-2, however, is secreted only upon CD28 costimulation. T-cell amplification was most effectively induced by the CD28f CAR and less by f and fOX40 CAR stimulation (Fig. 2B) . CD28f CAR engagement moreover induced secretion of IL-10 in high levels which were much lower without CD28 or with OX40 costimulation.
Since CD28 costimulation in contrast to OX40 additionally induced IL-2, we asked whether IL-10 secretion is induced by IL-2 independently of costimulation. To address the question in a thoroughly controlled setting, fCAR engineered T cells were specifically stimulated by the immobilized anti-idiotypic antibody BW2064, which is directed toward the scFv CAR domain, in presence or absence of added IL-2. As shown in Figure 3 , IL-2 enhanced, along with IFNc, IL-10 secretion of f CAR engineered T cells upon CAR engagement with antigen. IL-2 did not induce IL-10 secretion, however, when T cells were stimulated by the OX40f CAR. As controls IL-2 increased IL-10 secretion by CD28f CAR modified T cells whereas IL-2 did not induce IL-10 in non-modified T cells without f stimulation. Taken together, IL-2 in the context of f CAR signaling induced IL-10 which is not the case in presence of OX40 costimulation.
Since CD28f CAR signaling induced IL-2 secretion we asked whether IL-10 secretion is due to autocrine acting IL-2 upon CD28 mediated release. We abrogated IL-2 release by abrogating lck binding to CD28 by mutation of the lck binding motif in the CAR CD28 signaling moiety. CD4 + T cells were engineered with the mutated CD28Df CAR or for comparison with the f and CD28f CAR, respectively, and stimulated through binding to the CAR antigen. As summarized in Figure 4 , the CD28D CAR did not induce IL-2 secretion while IL-10 and IFNc secretion are not altered compared with the wild-type CD28f CAR. Cytokine secretion was specifically induced by CAR engagement of antigen because coincubation with an irrelevant antigen did not induce IL-10 secretion. Data indicate that at least two pathways can induce IL-10 secretion in CAR engineered T cells, one via IL-2 and the other via CD28 independently of IL-2 induction. 4 /well) in microtiter plates that were coated with 10 mg/ml of the CAR-specific anti-idiotypic mAb BW2064 which binds to the CAR BW431/26 scFv domain to specifically stimulate CAR T cells, or an isotype control mAb (IgG1). The number of CAR expressing T cells was adjusted to equal numbers by adding non-transduced cells from the same donor. Cytokines in the supernatant were recorded by ELISA, proliferation was determined by BrdU incorporation. Data represent the mean of triplicates ± standard error of the mean (SEM).
Since fOX40 CAR redirected T cells did not produce IL-10 in presence of added IL-2, we asked whether OX40 costimulation prevents CD28 mediated IL-10 secretion. To address the issue, we made use of a CD28-OX40 dual costimulatory CAR. For comparison, we used a CD28Df and CD28DOX40 CAR which were deficient in IL-2 induction. CARs were expressed in CD4 + T cells and triggered by immobilized, CAR-specific antigen. As summarized in Figure 5 , CD28f CAR T cells did not secrete IL-10 when costimulated by OX40. IL-10 is also repressed in presence of OX40 co-signaling when T cells were stimulated by the mutated CD28Df CAR. For comparison, all CARs induced similar amounts of secreted IFNc indicating a similar T cell activation potency. IL-2 is secreted upon CD28f and CD28fOX40 CAR signaling indicating the functional integrity of the CD28 domain while IL-2 is not induced by the mutant CD28Df and the CD28DOX40 CAR as expected. In summary, data indicate that OX40 in a combined CD28-OX40 CAR repressed CD28 induced IL-10 secretion by redirected T cells.
Treg cells are strong producers of IL-10. We therefore asked whether CAR mediated OX40 co-signaling does also repress 
IL-7R
-T cells were isolated from the peripheral blood (Fig. 6A ). Cells were activated and expanded as recently described. 23 Expanded cells were verified as Treg cells by a standard suppressor assay (Fig. 6B) . We engineered Treg cells with CD28f and The modified CD28Df CAR which lacks IL-2 induction also mediated IL-10 secretion. The anti-idiotypic mAb BW2064 which binds to the scFv domain of the CAR and an isotype control mAb IgG1 were coated onto microtiter plates (10 mg/ml coating solution). CD4 + T cells were engineered to express CARs with f, CD28f and CD28Df signaling domains, respectively, and incubated for 48 h in coated microtiter plates (2.5 ¾ 10 4 CAR T cells/well). Culture supernatants were tested by ELISA for IFNc, IL-2 and IL-10, respectively. The assays were performed three times in triplicates; data represent mean values ± SEM of a representative experiment.
CD28OX40 CARs with similar efficiencies (Fig. 6C) . Upon CD28f and CD28OX40 CAR redirected activation, Treg cells secreted same amounts of IFNc indicating a similar degree in CAR mediated activation (Fig. 6D) . No IL-2 is induced as expected for Treg cells. CD28f CAR modified Treg cells, however, secreted high amounts of IL-10 which were substantially reduced when redirected by the CD28OX40 CAR. Data indicate that OX40 costimulation as provided by a CD28OX40 CAR repressed IL-10 secretion in Treg cells as it did in effector T cells.
Discussion
We here demonstrate that CD28f CAR redirected T cells secrete high amounts of IL-10 which is also the case when f CAR T cells were stimulated in presence of IL-2. Since CD28Df CAR T cells which do not produce IL-2 upon CAR engagement still secrete IL-10 we conclude that IL-10 secretion by activated T cells can be induced by CD28 costimulation independently of IL-2 signaling. Simultaneous OX40 costimulation by a CAR repressed both IL-2 and CD28 mediated IL-10 secretion. IL-10 repression was not Figure 5 . OX40 costimulation repressed CD28 CAR mediated IL-10 secretion in redirected T cells. Serial dilutions of the anti-idiotypic mAb BW2064 and an isotype control mAb IgG1 were coated onto microtiter plates (0.01-10 mg/ml). CD4 + T cells were engineered with the CEA-specific CD28f, CD28Df, CD28OX40, and CD28DOX40 CAR, respectively, and incubated for 48 h in coated microtiter plates (2.5 ¾ 10 4 CAR T cells/well). Culture supernatants were recorded by ELISA for IFNc, IL-2 and IL-10, respectively. The assays were performed three times; data represent mean values of triplicates ± SEM of a representative experiment. www.landesbioscience.com OncoImmunologydue to an impaired overall signaling because IFNc and IL-2 secretion were not altered by OX40 costimulation.
Endodomains from single costimulatory molecules linked to CD3f in a CAR are sufficient to activate the killing machinery and to increase T-cell proliferation and IFNc release.
24 OX40 and 4-1BB CARs less enhance T cell proliferation when inserted in cis in a fCAR compared with a CD28f CAR.
24 OX40 cosignaling did not substantially increase the cytolytic activity and T cell amplification. While CD3f CAR T cells fail to sustain their function in the long-term, T cells redirected by the CD28-OX40 CAR produced lasting anti-tumor activity in a xenograft metastatic model. 6 ,25 CD28-OX40 redirected T cells, however, were unable to completely eradicate the disease which may be due in part to inefficiently sustaining human T cell function in the mouse. We assume that the combined CD28-OX40 CAR signaling moreover promotes the expansion of naïve T cells in absence of the appropriate ligands on target cells or APCs. While CD28 activation initiates clonal expansion of naïve T cells and IL-2 secretion, in the absence of additional cooperative signals only a small number of antigen-responding T cells persist and the majority of T cells undergo apoptosis. 26 In this context fusion of the "late" costimulatory OX40 signal in cis to the CD28f "early" signal in a combined CAR will be of benefit compared with OX40 or CD28 costimulation only. Consequently, incorporation of the OX40 signaling domain favors the expansion, persistence and effector functions of those cells 27 which likely occurs because both costimulatory domains produce greater activation of NFkB than either domain alone. CD28 and OX40 activate NFkB by different pathways, i.e., CD28 via Vav and PI3K and OX40 via TRAF2. NFkB independent signals via Akt and AP1 are additionally transmitted. 10, 28 The different costimulatory CARs produce different patterns of secreted cytokines; CD28f CAR T cells in particular produce IL-2 and IL-10 which both were not secreted by fOX40 CAR T cells. 25 T cells redirected by the CD28-OX40 CAR produced IL-2 and increased IFNc after stimulation which is in accordance to previous reports. 6, 15 The CD28Df CAR which did not produce IL-2 due to the mutated lck binding domain in the CD28 signaling moiety displays a more favorite panel of secreted cytokines with high IFNc levels without providing IL-2 supporting Treg cell survival and repression. 29 Proliferation of engineered effector T cells is likewise sustained by the modified CAR. Pule et al. 15 reported that CD3f and OX40f CAR T cells did not produce IL-10, which is in accordance to our observation, CD28-OX40 CAR T cells, however, were found to secrete IL-10 in nearly the same but hardly detectable levels as CD28 CAR T cells. The divergent observation may be due to the different arrangement of the signaling domains in cis described in the Pule report, 15 i.e., a CAR with CD28 followed by OX40 followed by CD3f, whereas we used a CAR with OX40 in a terminal position. Both CARs have CD28 in a membrane proximal position and have the same trans-membrane domain which determines the level of surface CAR expression. 30 CARs in which CD28 is merely membrane distal are not functional in CD3f costimulation. 31 CARs with CD28 trans-membrane domain show higher expression on the T-cell surface than CARs with a CD3f membrane domain which is in accordance to Pule et al. 15 Combining "early" with "late" costimulatory signals in cis in a CAR, however, has its limitation since it does not completely recapitulate the temporo-spatial features of the sequential signaling events as they physiologically occur to sustain T-cell activation. 7, 27 Repression of IL-10 by signaling through a CD28-f-OX40 CAR likely prevents auto-repression of CAR redirected T cells through a prolonged cellular immune response. IL-10 repression will moreover be of interest when combining the "T-body" approach with vaccination against tumor associated antigens 32 and prevent accumulation of IL-10 in the tumor microenvironment that in turn may compromise the anti-tumor response. 16 There may be concerns to transduce T cells by a retrovirus with a CAR with strong and lasting proliferative signals. Retroviral integration potentially can induce T cell acute lymphoblastic leukemia due to LMO2 overexpression in patients with X-linked severe combined immunodeficiency who received hematopoietic stem cells engineered to constitutively express the common c-chain receptor. 33 In contrast to retroviral modification of hematopoietic stem cells, engineering mature T cells in experimental models did not or very rarely result in malignant transformation.
34,35

Materials and Methods
Cell lines and reagents. 293T cells are human embryonic kidney cells that express the SV40 large T antigen. 36 The CEAexpressing colon carcinoma cell line LS174T (ATCC CCL 188) and the CEA-negative cell line Colo320 (ATCC CCL 220.1) were obtained from ATCC. The anti-CEA mAb BW431/26 and the anti-id mAb BW2064/36 with specificity for the anti-CEA mAb BW431/26 were described earlier.
37 OKT3 (ATCC CRL 8001) is a hybridoma cell line that produces the anti-CD3 mAb OKT3. All cell lines were cultured in RPMI 1640 medium, 10% (v/v) FCS (all Life Technologies). OKT3 mAb was affinity purified from hybridoma supernatants utilizing goat anti-mouse IgG2a antibodies (Southern Biotechnology) that were immobilized on N-hydroxy-succinimid-ester-(NHS)-activated sepharose as recommended by the manufacturer (Amersham Biosciences). The goat anti-human IgG antibody and its biotin-, FITC-or PEconjugated F(ab´) 2 derivatives were purchased from Southern Biotechnology. The anti-IFNc mAb NIB42 and the biotinylated anti-IFNc mAb 4S.B3, the anti-IL-2 mAb 5344.111 and the biotinylated anti-IL-2 mAb B33-2, and the anti-human IL-10 mAb 4D5 and the biotinylated anti-human IL-10 mAb 6D4/D6/ G2 were all purchased from BD Bioscience.
Generation and expression of recombinant anti-CEA CARs. The generation of the retroviral expression cassettes for the recombinant BW431/26-scFv-Fcf, the BW431/26-scFv-FcCD28f, the BW431/26-scFv-Fc-OX40 and the BW431/26-scFv-Fc-CD28OX40 CARs was described in detail. 4, 24, 38 Retroviral transduction of T cells with CARs was described in detail elsewhere; 36, 38 CAR expression was monitored by flow cytometric analyses. Isolation, propagation and retroviral gene transfer of CD4
high regulatory T cells was performed as recently described. 23 The CD28 endodomain with a mutated Lck binding motive was generated by site-directed mutagenesis. Briefly, retroviral expression vectors for recombinant CARs harboring a chimeric CD28f or CD28OX40 signaling domain were PCR-amplified utilizing the following oligonucleotids: S-CD28D (sense): CCCACCCGCAAGCATTACCAG GCCTATGCCGCCGCACGCGACTTCGCAGCCTAT; ASCD28d (antisense): ATAGGCTGCGAAGTCGCGTGCGGCG GCATAGGCCTGGTAATGCTTGCGGGTGGG.
The reaction product was treated with DpnI, transformed into E. coli DH5, and mutations were verified by sequence analysis.
Magnetic activated cell sorting (MACS). Peripheral blood lymphocytes from healthy donors were isolated by density centrifugation and monocytes were depleted by plastic adherence. Non-adherent lymphocytes were washed with cold PBS containing 0.5% (w/v) BSA, 1% (v/v) FCS, 2 mM EDTA. CD4 + T cells were isolated by magnetic activated cell sorting (MACS) utilizing the "CD4 + T cell isolation kit" (Miltenyi Biotec) routinely resulting in . 95% purity. CD4 + CD25 +
FoxP3
high Treg cells were isolated utilizing the "Treg isolation kit II" (Miltenyi Biotec).
Immunofluorescence analyses. CAR engineered T cells were identified by two color immunofluorescence utilizing a PEconjugated F(ab') 2 anti-human IgG1 antibody (0.1 mg/ml) and a FITC-conjugated anti-CD3 mAb (UCHT-1, 1:20). Regulatory T cells were identified by multi color immunofluorescence utilizing an APC-conjugated anti-CD4 mAb (Dako), a PEconjugated anti-CD25 mAb (Miltenyi) and a FITC-conjugated anti-CD127 (IL-7R) mAb (eBioscience). Immunofluorescence was analyzed using a FACScan TM cytofluorometer equipped with the CellQuest research software (Becton Dickinson).
CAR mediated T cell activation. CD4 + T cells were engineered with anti-CEA CARs and cultivated in the presence or absence of exogenous IL-2 (10-1,000 U/ml) in microtiter plates (Polysorb, Nunc, Roskilde, Denmark) (2.5 ¾ 10 4 receptor grafted T cells/well) which were pre-coated with the anti-idiotypic mAb BW2064 or an IgG1 mAb for control (each 0.01-10 mg/ml). In another set of experiments CAR engineered T cells were cocultivated for 48 h in 96-well round bottom plates with CEA + LS174T and CEA -Colo320 tumor cells (each 2.5 ¾ 10 4 cells/well). After 48 h culture supernatants were analyzed by ELISA for IFNc, IL-2 and IL-10 secretion, respectively. Briefly, cytokines in the supernatants were bound to the solid phase capture antibodies (each 1 mg/ml) and detected by the biotinylated detection antibodies (each 0.5 mg/ml). The reaction product was visualized by a peroxidase-streptavidin-conjugate (1:10,000) and ABTS 1 (Roche Biochemicals, Mannheim, Germany). T cell proliferation was determined by BrdUincorporation utilizing the "5-Bromo-2'-deoxy-uridine Labeling and Detection Kit III" (Roche Biochemicals).
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